SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJudges Scientific Regulatory News (JDG)

Share Price Information for Judges Scientific (JDG)

Share Price is delayed by 15 minutes
Get Live Data
4,490.00    40.00 (0.90%)
Bid:
4,400.00
Ask:
4,580.00
Spread: 180.00 (4.091%)
Market Cap: £299.07m
JDG Live PriceLast checked at - London Stock Exchange

Intraday Judges Scientific Share Chart

Trading Statement

18 Jul 2012 07:00

RNS Number : 8953H
Judges Scientific PLC
18 July 2012
 

 

 

Judges Scientific plc

Trading Statement

18 July 2012

Judges Scientific plc ('Judges Scientific', the 'Company' or the 'Group')

Trading Update

The Directors of Judges Scientific, the parent company of a group engaged in the design, manufacture and sale of scientific instruments, are pleased to update shareholders and the market with regard to the Group's trading performance during the first half of the current financial year.

The Group recorded a solid trading performance during the period to 30 June 2012. The interim results, scheduled to be announced in September, are expected to show organic revenue growth of almost 8% compared with the six months to 30 June 2011. This advance in revenue increases to 39% when account is taken of businesses purchased since 1 January 2011, including a full six months of turnover from Deben and a first time contribution from Global Digital Systems ("GDS") and KE Developments ("KED"). The Board anticipates that interim profits and earnings per share before exceptional items will reflect this satisfactory performance.

GDS and KED were acquired on 6 March 2012 and both have since traded in line with management's expectations. The KED business was successfully relocated into Deben's Woolpit premises during the course of June 2012.

Order intake during the six-month period showed organic growth of 14%. The order book at 30 June 2012 represented ten weeks of sales, somewhat ahead of the level at the beginning of the year, partly as a result of the strong order intake and partly due to the fact that GDS's order book tends to be longer than the Group average.

The balance sheet will show a comfortable cash surplus as at 30 June 2012. Net debt had been eliminated altogether by the end of February, before £8.0 million was borrowed in March to finance the acquisition of GDS. However, the share placing in May raised £2.8 million (net) and this can be assumed to have reduced the level of gearing to less than one-times pro-forma historic EBITA.

The Board continues to be mindful that the global economic climate is fraught with uncertainty. Public spending restraint in Europe, the strength of Sterling, the embattled status of the Euro and fears of deceleration in China are all factors which are capable of affecting our businesses. There can be no complacency and the Board views the current trading environment with balanced measures of vigilance and confidence.

Enquiries:

David Cicurel, CEO, Judges Scientific: Tel: 01342 323 600

Pascal Keane, Edwards Mansfield, Shore Capital: Tel: 020 7408 4090

Melvyn Marckus, Cardew Group: Tel: 07775 896 491

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTZMGMNRNRGZZM
Date   Source Headline
6th Apr 20232:50 pmRNSDirector/PDMR Shareholding
4th Apr 202312:21 pmRNSTotal Voting Rights
3rd Apr 20237:01 amRNSAcquisition of Henniker Scientific Limited
3rd Apr 20237:00 amRNSAppointment of Joint Broker
31st Mar 20238:54 amRNSGrant of Options
22nd Mar 20237:00 amRNSFinal Results
8th Mar 20232:39 pmRNSTotal Voting Rights
8th Mar 20237:00 amRNSDirector/PDMR Shareholding
13th Feb 20238:48 amRNSDirector/PDMR Shareholding
2nd Feb 20239:17 amRNSDirector/PDMR Shareholding
1st Feb 20237:00 amRNSExecutive Director and Board Appointment
1st Feb 20237:00 amRNSTotal Voting Rights
23rd Jan 202310:27 amRNSGrant of Options
19th Jan 20237:00 amRNSFull Year Trading Statement and Notice of Results
9th Jan 20237:00 amRNSDirector/PDMR Shareholding
3rd Jan 20231:03 pmRNSTotal Voting Rights
21st Dec 202210:51 amRNSBlock listing Interim Review
20th Dec 202211:53 amRNSDirector/PDMR Shareholding
12th Dec 20228:52 amRNSHolding(s) in Company
6th Dec 20222:34 pmRNSDirector/PDMR Shareholding
1st Dec 202210:01 amRNSTotal Voting Rights
30th Nov 20224:41 pmRNSSecond Price Monitoring Extn
30th Nov 20224:35 pmRNSPrice Monitoring Extension
17th Nov 20228:54 amRNSDirector/PDMR Shareholding
7th Nov 20225:14 pmRNSDirector/PDMR Shareholding
7th Oct 20227:00 amRNSDirector/PDMR Shareholding
4th Oct 20223:55 pmRNSDirector/PDMR Shareholding
3rd Oct 202210:01 amRNSTotal Voting Rights
23rd Sep 20223:44 pmRNSDirector/PDMR Shareholding
22nd Sep 20227:00 amRNSInterim Results
6th Sep 20222:51 pmRNSDirector/PDMR Shareholding
2nd Sep 20223:16 pmRNSTotal Voting Rights
9th Aug 20229:20 amRNSDirector/PDMR Shareholding
1st Aug 202211:07 amRNSTotal Voting Rights
27th Jul 20224:08 pmRNSDirector/PDMR Shareholding
25th Jul 20227:00 amRNSHalf Year Trading Update and Notice of Results
8th Jul 20228:12 amRNSDirector/PDMR Shareholding
1st Jul 20225:34 pmRNSTotal Voting Rights
29th Jun 202211:13 amRNSDirector/PDMR Shareholding
27th Jun 20227:00 amRNSAcquisition of minority shareholding in Bordeaux
21st Jun 20227:00 amRNSDirector/PDMR Shareholding
10th Jun 202211:43 amRNSBlocklisting Return
9th Jun 202212:11 pmRNSDirector/PDMR Shareholding
9th Jun 20227:36 amRNSIssue of Shares – Replacement
8th Jun 20223:52 pmRNSIssue of Ordinary Shares
6th Jun 20223:00 pmRNSPurchase of Ordinary Shares
1st Jun 202212:48 pmRNSTotal Voting Rights
27th May 20221:08 pmRNSAppointment of auditor
24th May 20222:12 pmRNSResult of AGM
23rd May 202211:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.